1. 127POutcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). (24th November 2019) Authors: Chan, S L; Miksad, R; Cicin, I; Chen, Y; Klumpen, H J; Kim, S; Lin, Z Z; Youkstetter, J; Sen, S; Cheng, A-L; El-Khoueiry, A B; Meyer, T; Kelley, R K; Abou-Alfa, G K Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). (2nd July 2019) Authors: Miksad, R; Cicin, I; Chen, Y; Klumpen, H; Kim, S; Lin, Z; Youkstetter, J; Sen, S; Cheng, A; Meyer, T; Kelley, R; Abou-Alfa, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗